Skip to main
COYA

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics is looking to be a promising long-term investment with its focus on developing therapies for neurodegenerative and inflammatory diseases. With a strong pipeline, the company is expected to achieve positive clinical data from ALSTARS and its upcoming phase II study of COYA 302 in frontotemporal dementia. Although risks to financial performance and valuation exist, the company's biomarker strategy and combination therapies show potential for success in the market.

Bears say

Coya Therapeutics is a clinical-stage biotechnology company that is focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). However, the company faces significant competition in the biotechnology and pharmaceutical industries, and its product pipeline is still in the early stages with no products generating revenue. Additionally, the company will likely need to raise additional capital in the future, which may be difficult to obtain depending on market conditions. There is also a risk that the company's key intellectual property may fail to protect its products.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.